Genotoxicity induced by iodine-131 in human cultured lymphocytes.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3798859)

Published in Interdiscip Toxicol on June 01, 2013

Authors

Seyed Jalal Hosseinimehr1, Nayereh Shafaghati, Monireh Hedayati

Author Affiliations

1: Department of Radiopharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.

Articles cited by this

The in vitro micronucleus technique. Mutat Res (2000) 5.22

Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid (2009) 2.79

Radiation carcinogenesis. Carcinogenesis (2000) 2.41

Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer (2011) 1.71

The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med (2004) 1.68

The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol (1986) 1.53

The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med (2005) 1.35

Therapy-related myeloid neoplasms following treatment with radioiodine. Haematologica (2011) 1.06

Micronuclei induction by 131I exposure: study in hyperthyroidism patients. Mutat Res (1997) 1.02

Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON (2007) 0.95

Flavonoids and genomic instability induced by ionizing radiation. Drug Discov Today (2010) 0.93

Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer (1997) 0.92

Incidence of second primary malignancies during a long-term surveillance of patients with differentiated thyroid carcinoma in relation to radioiodine treatment. Clin Nucl Med (2011) 0.89

Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis (2000) 0.89

Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease. Pharmacotherapy (2005) 0.88

Formation of micronuclei and of clastogenic factor(s) in patients receiving therapeutic doses of iodine-131. Mutat Res (2002) 0.88